However, the CD44+/CD24- phenotype in ovarian cancer cells determines the CSC properties of newly propagated and invasive tumors, and ovarian cancer patients with this phenotype exhibit enhanced recurrence and shorter progression-free survival [56]. This evidence concerns the gene CD24 and ovarian cancer.